The PFI results of Log-rank test indicated that expression of ARPC5 was negatively correlated with PFS in patients with BLCA, HNSC, KIRC, KIRP, LGG, LIHC, and PRAD (Supplementary Figure S1). This evidence concerns the gene ARPC5 and bladder transitional cell carcinoma.